Chinese Hamster Ovary (i.e., Cho) Patents (Class 435/358)
-
Publication number: 20150044753Abstract: The present invention relates to a vector comprising a polynucleotide encoding a modified glutamine synthetase (GS), and a method for preparing a target protein employing the same. More particularly, the present invention relates to a modified GS having an increased sensitivity to a glutamine synthetase (GS) inhibitor, a polynucleotide encoding the modified GS, a vector comprising the polynucleotide, a transformant comprising the vector, and a method for preparing a target protein using the transformant.Type: ApplicationFiled: March 5, 2013Publication date: February 12, 2015Inventors: Hyun Sook Jang, Dong Heon Lee, Sun Kyu Kim, Yong Ho Ahn, Sang Kyung Park
-
Publication number: 20150044768Abstract: The method of the invention provides for producing a heterologous protein in mammalian host cells having nucleic acid encoding Hepatitis B X protein and the heterologous protein, by growing mammalian host cells selected from the group consistng of HKB11, CHO, BHK21, C2C12, and HEK293 cells, by growing mammalian host cells in non-adherent suspension culture, or by growing mammalian host cells which contain nucleic acid providing exogenous X-box Binding Protein, XBP1s. The conditions should be such that HBx, exogenous XBP1s if present, and the heterologous protein are expressed by the mammalian cells. The invention includes compositions for carrying out the method.Type: ApplicationFiled: October 24, 2014Publication date: February 12, 2015Inventors: FANG JIN, RICHARD N. HARKINS, MAXINE BAUZON, TERRY HERMISTON
-
Publication number: 20150044769Abstract: A cell of a cell line adapted to a protein-free and lipid-free medium, which is derived from CHO cells, can be stably used for production of recombinant proteins and can proliferate in a suspended state in a protein-free and lipid-free medium containing no exogenous growth factors. A method for adapting CHO cells by using a protein-free and lipid-free medium and a medium used for the method.Type: ApplicationFiled: February 21, 2014Publication date: February 12, 2015Applicant: Kyokuto Pharmaceutical Industrial Co., Ltd.Inventor: Tetsuji Sasaki
-
Publication number: 20150038675Abstract: The purpose of the present invention is to provide: a peptide having an affinity for silicon nitride; a polynucleotide encoding the peptide; an expression vector for expressing the peptide having an affinity for silicon nitride; an expression vector for expressing a peptide fusion protein that comprises the peptide having an affinity for silicon nitride and a target protein; a transformant obtained by introducing the expression vector into a host cell; a peptide fusion protein obtained from the transformant; a silicon nitride substrate to which a peptide having an affinity for silicon nitride has been bonded; a method for immobilizing a target protein to a silicon nitride substrate; a composition for immobilizing a target protein to a silicon nitride substrate, the composition comprising a peptide having an affinity for silicon nitride; and a linker for immobilizing a target protein to a silicon nitride substrate, the linker comprising a peptide having an affinity for silicon nitride.Type: ApplicationFiled: February 12, 2013Publication date: February 5, 2015Inventors: Yoichi Kumada, Michimasa Kishimoto, Takeru Otsuka
-
Publication number: 20150037284Abstract: The present invention relates to a novel Listeria bacteriophage designated ProCC P825. In particular, the present invention relates to the endolysin PlyP825 encoded by the novel phage ProCC P825 and uses of the novel endolysin PlyP825 for controlling Listeria contamination and infection.Type: ApplicationFiled: May 29, 2012Publication date: February 5, 2015Applicant: DSM IP ASSETS B.V.Inventors: Holger Grallert, Julia Lorenz, Anna Scherzinger
-
Publication number: 20150040252Abstract: The invention relates to isolation of novel ?-actin and ribosomal protein S21 (rpS21) promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent ?-actin promoters including, hamster, rat, and mouse, and hamster rpS21 promoter.Type: ApplicationFiled: August 1, 2014Publication date: February 5, 2015Applicant: GENZYME CORPORATIONInventors: Scott D. ESTES, Weiqun ZHANG
-
Patent number: 8945877Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density and strength. In certain embodiments, the present invention provides ALK3 polypeptides, including ALK3-Fc fusion proteins.Type: GrantFiled: December 21, 2012Date of Patent: February 3, 2015Assignee: Acceleron Pharma, Inc.Inventor: Jasbir Seehra
-
Publication number: 20150031128Abstract: The invention pertains to the use of (i) one or more C2-C6 alpha-hydroxy acids, salts of these acids, esters of these acids and combinations thereof; and (ii) one or more compounds selected from—the group of amino acid derivatives consisting of ?-glutamyl amino acids, pyroglutamyl amino acids, glutamate-containing or proline-containing dipeptides, oxo-aminoacids, homo-amino acids, N-acetyl amino-acids and glycyl-glycine; -phenolic acid derivatives; -linear C2-C6 or cyclic C6 sugar alcohols; -pyridinic acid derivatives; and -nucleobases and/or nucleotides chosen from uracil, adenine, adenosine 3?-monophosphate (3?-AMP) and adenosine 5?-monophosphate (AMP), as a growth-and production promoting ingredient, in culture media for culturing eukaryotic cells. The invention further pertains to culture media containing these components at levels of at least 0.001 mg/l.Type: ApplicationFiled: March 8, 2013Publication date: January 29, 2015Applicant: Friesland Brands B.V.Inventors: Abhishek Gupta, Mireille Maria Gadellaa, Dominick Yves Willy Maes
-
Publication number: 20150031618Abstract: The present disclosure relates to a collection of novel muteins derived from human ?1m (or a1m) polypeptide or a functional homologue thereof. The disclosure further refers to a ?1m mutein capable of specifically binding to one or more targets other than a target to which wild-type ?1m binds. The disclosure also relates to a method for producing such collection of muteins and a method for isolating a mutein capable of binding one or more such non-natural targets of wild-type ?1m polypeptide. These aspects are made possible due to, e.g, the structural elucidation of ?1m disclosed herein by the present inventors, an appreciation of ligand-binding sights thereof and, hence, an understanding of which amino acid positions are most suitable for mutagenesis for re-engineering specificity and affinity for any given target while maintaining the secondary and/or tertiary structure of ?1m.Type: ApplicationFiled: January 31, 2013Publication date: January 29, 2015Inventors: Arne Skerra, Winfried Meining, Evelyn Eggenstein
-
Patent number: 8940504Abstract: The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.Type: GrantFiled: March 13, 2012Date of Patent: January 27, 2015Assignee: Novo Nordisk Healthcare AGInventors: Thomas Dock Steenstrup, Peder Lisby Norby
-
Publication number: 20150023959Abstract: The present invention provides a VWF fragment comprising the D? domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.Type: ApplicationFiled: January 12, 2013Publication date: January 22, 2015Applicant: BIOGEN IDEC MA INC.Inventors: Ekta Seth Chhabra, Tongyao Liu, Robert T. Peters, Haiyan Jiang
-
Publication number: 20150024485Abstract: This invention relates to industrial production of proteins. More specifically, the invention relates to the res-DHFR surrogate marker, which corresponds to a fusion between DHFR and a protein conferring resistance to a toxic compound or conferring a metabolic advantage. The invention further relates to the use of res-DHFR for screening cells for high expression of a protein of interest. The invention is illustrated by the Puro-DHFR surrogate marker, which corresponds to a fusion between the puromycin N-acetyltransferase and dihydrofolate reductase (DHFR).Type: ApplicationFiled: September 10, 2014Publication date: January 22, 2015Inventors: MICHEL KOBR, PHILIPPE DUPRAZ
-
Publication number: 20150023988Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: January 22, 2015Applicant: AMGEN INC.Inventors: Justin K. MURRAY, Jerry Ryan HOLDER, Malgorzata WANSKA, Christopher M. TEGLEY, James R. FALSEY, Elizabeth M. DOHERTY, Leslie P. MIRANDA
-
Publication number: 20150023960Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.Type: ApplicationFiled: March 8, 2013Publication date: January 22, 2015Inventors: Darrin Anthony Lindhout, Peng Zhang, Thomas Frederick Parsons
-
Publication number: 20150017717Abstract: The invention pertains to the use of C2-C6alpha-hydroxy acids selected from L-3-phenyl lactic acid, mucic (galactaric) acid, gluconic acid, glucaric acid, glyceric acid, 2-hydroxy butyric acid, alpha-hydroxyisovaleric acid, alpha-hydroxyisocaproic acid and erythronic acid and combinations thereof, as a growth- and production promoting ingredient, in culture media for culturing eukaryotic cells. The invention further pertains to culture media containing these alpha-hydroxy acid derivatives at levels of at least 0.001 mg/l.Type: ApplicationFiled: March 8, 2013Publication date: January 15, 2015Applicant: Friesland Brands B.V.Inventors: Abhishek Gupta, Mireille Maria Gadellaa, Dominick Yves Willy Maes
-
Publication number: 20150018522Abstract: Disclosed are mutants of galactosyltransferases that can catalyze formation of oligosaccharides in the presence of magnesium; mutants of galactosyltransferases having altered donor and acceptor specificity which can catalyze formation of oligosaccharides in the presence of magnesium; methods and compositions that can be used to synthesize oligosaccharides; methods for increasing the immunogenicity of an antigen; and methods to stabilize platelets.Type: ApplicationFiled: March 10, 2014Publication date: January 15, 2015Applicant: The United States of America, as represented by the Secretary, Department of Health & Human ServicInventors: Pradman K. Qasba, Elizabeth Boeggeman, Boopathy Ramakrishnan
-
Publication number: 20150017695Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.Type: ApplicationFiled: September 30, 2014Publication date: January 15, 2015Inventors: Jack Liang, Stephane J. Jenne, Emily Mundorff, Charlene Ching, John M. Gruber, Anke Krebber, Gjalt W. Huisman
-
Publication number: 20150020221Abstract: The invention provides methods and compositions for enhancing the efficacy of cancer therapies through modulation of BAL1 and/or BBAP. Also provided are methods for predicting the efficacy of cancer therapies or treating cancer in a subject through modulation of BAL1 and/or BBAP. Further provided are methods for identifying compounds that are capable of modulating BAL1-BBAP complexes.Type: ApplicationFiled: October 5, 2012Publication date: January 15, 2015Inventors: Margaret A. Shipp, Qingsheng Yan
-
Publication number: 20150010529Abstract: Modified PH20 hyaluronidase polypeptides that exhibit stability and activity under thermal stress conditions are provided. Also provided are compositions and formulations and uses thereof.Type: ApplicationFiled: July 3, 2014Publication date: January 8, 2015Inventor: Ge Wei
-
Publication number: 20150010532Abstract: The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.Type: ApplicationFiled: July 11, 2014Publication date: January 8, 2015Inventor: Wayne K. Herber
-
Publication number: 20150011733Abstract: Disclosed are methods of making collagen 7, or functional fragments thereof, as well as collagen 7, and functional fragments thereof produced by such methods, nucleic acids encoding collagen 7, and functional fragments thereof, as well as vectors and host cells comprising such nucleic acids.Type: ApplicationFiled: August 3, 2012Publication date: January 8, 2015Inventors: Malini Viswanathan, Mark DeSouza
-
Patent number: 8926981Abstract: The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays.Type: GrantFiled: September 12, 2012Date of Patent: January 6, 2015Assignee: Diagnostic Hybrids, Inc.Inventor: James L. Brown
-
Patent number: 8921537Abstract: The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies.Type: GrantFiled: March 3, 2011Date of Patent: December 30, 2014Assignee: Genentech, Inc.Inventors: Germaine Fuh, Chingwei V. Lee
-
Publication number: 20140377407Abstract: This invention relates to a novel alpha-amylase, a process for its preparation and the use of the amylase. The invention relates to a newly identified polynucleotide sequence from Alicyclobacillus pohliae comprising a gene that encodes the novel alpha-amylase enzyme. The invention features the full length coding sequence of the novel gene as well as the amino acid sequence of the full-length functional protein of the gene. The invention also relates to methods of using these proteins in industrial processes, for example in food industry, such as the baking industry. Also included in the invention are cells transformed with a polynucleotide according to the invention suitable for producing these proteins and cells.Type: ApplicationFiled: January 29, 2013Publication date: December 25, 2014Applicant: DSM IP ASSETS B.V.Inventor: Lucie Parenicova
-
Publication number: 20140377800Abstract: The present invention relates to methods of optimization of a protein coding sequences for expression in a given host cell. The methods apply genetic algorithms to optimise single codon fitness and/or codon pair fitness sequences coding for a predetermined amino acid sequence. In the algorithm generation of new sequence variants and subsequent selection of fitter variants is reiterated until the variant coding sequences reach a minimum value for single codon fitness and/or codon pair fitness. The invention also relates to a computer comprising a processor and memory, the processor being arranged to read from and write into the memory, the memory comprising data and instructions arranged to provide the processor with the capacity to perform the genetic algorithms for optimisation of single codon fitness and/or codon pair fitness.Type: ApplicationFiled: May 20, 2014Publication date: December 25, 2014Inventors: Johannes Andries ROUBOS, Noel Nicolaas Maria Elisabeth VAN PEIJ
-
Publication number: 20140377840Abstract: A nucleic acid sequence, including an isolated, purified or recombinant nucleic acid sequence, includes: (a) a nucleic acid sequence encoding a polypeptide for stimulating embryonic development, namely, a PLC-zeta; PLC? amino acid sequence, capable of triggering calcium oscillations in oocytes; (b) a sequence substantially homologous to or that hybridizes to sequence (a) under stringent conditions; (c) a sequence substantially homologous to or that hybridizes to the sequences (a) or (b) but for degeneracy of the genetic code; and (d) an oligonucleotide specific for any of the sequences (a), (b) or (c) above.Type: ApplicationFiled: April 14, 2014Publication date: December 25, 2014Inventor: Francis Anthony Lai
-
Patent number: 8911964Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.Type: GrantFiled: March 26, 2014Date of Patent: December 16, 2014Inventors: Itzcoatl A. Pla, Joseph G. Matuck, John C. Fann, Christof Schulz, Nichole A. Roy, David F. Bruton, James McIntire, Yu-Hsiang David Chang, Thomas Seewoester
-
Patent number: 8911776Abstract: The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue.Type: GrantFiled: October 26, 2012Date of Patent: December 16, 2014Inventor: Claresa Levetan
-
Publication number: 20140363887Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.Type: ApplicationFiled: August 22, 2014Publication date: December 11, 2014Applicant: STEM CENTRX, INC.Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
-
Patent number: 8906393Abstract: Polysaccharide-containing extracts isolated from a host cell containing nucleotide sequences encoding genes pamA, pamB and pamC, wherein the extract is capable of inhibiting biofilm formation produced by gram-negative bacteria, gram-positive bacteria and fungi, and methods to inhibit biofilm formation or remove biofilms that have already formed.Type: GrantFiled: January 26, 2012Date of Patent: December 9, 2014Assignee: Rutgers, The State University of New JerseyInventors: Jeffrey B. Kaplan, Nataliya V. Balashova, Scott C. Kachlany, Evguenii Vinogradov
-
Patent number: 8906646Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.Type: GrantFiled: March 26, 2014Date of Patent: December 9, 2014Assignee: AbbVie Inc.Inventors: Itzcoatl A. Pla, Joseph G. Matuck, John C. Fann, Christof Schulz, Nichole A. Roy, David F. Bruton, James McIntire, Yu-Hsiang David Chang, Thomas Seewoester
-
Publication number: 20140356944Abstract: The present disclosure provides engineered transaminase polypeptides having improved properties as compared to naturally occurring transaminases including the ability of converting the substrate, 3?-hydroxyacetophenone to (S)-3-(1-aminoethyl)-phenol in enantiomeric excess and high percentage conversion. Also provided are polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to synthesize (S)-3-(1-aminoethyl)-phenol and related compounds useful in the production of active pharmaceutical ingredients.Type: ApplicationFiled: August 19, 2014Publication date: December 4, 2014Inventors: Fabien Louis Cabirol, Anupam Gohel, Seong Ho Oh, Derek J. Smith, Brian Wong, James J. Lalonde
-
Publication number: 20140356912Abstract: The present invention relates to the the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.Type: ApplicationFiled: July 28, 2014Publication date: December 4, 2014Inventors: Christopher N. Boddy, Susan M. Logan, Benjamin R. Lundgren, Ian C. Schoenhofen, Dennis M. Whitfield
-
Publication number: 20140356871Abstract: The disclosure relates to the field of human genetics, particularly the field of peripheral neuropathy, particularly inherited peripheral neuropathy. Specifically, the disclosure relates to methods and materials to detect hereditary peripheral neuropathy, more particularly autosomal recessive Charcot-Marie-Tooth disease.Type: ApplicationFiled: January 10, 2013Publication date: December 4, 2014Applicant: VIB VZWInventors: Albena Jordanova, Magdalena Zimon, Jonathan Baets, Peter De Jonghe
-
Publication number: 20140356347Abstract: The present disclosure provides novel variants of enzymes exhibiting serine protease activity; nucleic acid molecules encoding said proteases, vectors, host cells containing the nucleic acids and methods for preparation and producing such enzymes; compositions and complexes comprising at least one of the proteases; and methods for using such enzymes as a part of an immunoprotease, in particular for the treatment of cancer.Type: ApplicationFiled: September 21, 2012Publication date: December 4, 2014Inventors: Stefan Barth, Sonja Schiffer, Grit Hehmann-Titt
-
Publication number: 20140357564Abstract: The present invention relates to a polypeptide comprising a modified von Willebrand Factor (VWF) having a higher Factor VIII binding affinity than non-modified VWF, its pharmaceutical use and method of its preparation.Type: ApplicationFiled: February 14, 2013Publication date: December 4, 2014Inventors: Stefan Schulte, Thomas Weimer, Kay Hofmann
-
Publication number: 20140356326Abstract: The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.Type: ApplicationFiled: December 10, 2013Publication date: December 4, 2014Applicant: Amunix Operating Inc.Inventors: Volker Schellenberger, Willem P. Stemmer, Chia-Wei Wang, Michael D. Scholle, Mikhail Popkov, Nathaniel C. Gordon, Andreas Crameri
-
Publication number: 20140356346Abstract: The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.Type: ApplicationFiled: May 15, 2014Publication date: December 4, 2014Applicant: CSL Behring GmbHInventors: Thomas WEIMER, Stefan SCHULTE, Ulrich KRONTHALER, Wiegand LANG, Uwe LIEBING, Wilfried WORMSBÄCHER
-
Publication number: 20140350082Abstract: The invention provides, in one aspect, peptides and a complex comprising one of the peptides and a cargo molecule, wherein the peptide and the cargo molecule are coupled by non-covalently. The peptides of the invention were found to facilitate the delivery of siRNA molecules into cells and to function in siRNA mediated silencing of cellular targets.Type: ApplicationFiled: November 23, 2012Publication date: November 27, 2014Inventors: Pu Chen, Mousa Jafari, Wen Xu, Baoling Chen, Ran Pan, Nedra Karunaratne
-
Publication number: 20140349341Abstract: The present invention provides cell lines deficient in mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase I (Mgat1). Also provided are methods for producing the Mga1 deficient cell lines and methods for using the Mgat1 deficient cell lines for the production of recombinant proteins having simple glycoforms.Type: ApplicationFiled: January 10, 2013Publication date: November 27, 2014Applicant: SIGMA-ALDRICH CO. LLCInventors: Nan Lin, Natalie Sealover, Henry George, Kevin Kayser
-
Publication number: 20140348817Abstract: Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided.Type: ApplicationFiled: August 14, 2014Publication date: November 27, 2014Inventors: Ping Jiang, H. Michael Shepard, Lei Huang
-
Publication number: 20140342412Abstract: The present disclosure relates to transaminase polypeptides capable of aminating a dicarbonyl substrate, and polynucleotides, vectors, host cells, and methods of making and using the transaminase polypeptides.Type: ApplicationFiled: September 7, 2012Publication date: November 20, 2014Applicant: CODEXIS, INC.Inventors: Fabien Cabirol, Haibin Chen, Anupam Gohel, Paulina Salim, Derek Smith, Jacob Janey, Birgit Kosjek, Weng Lin Tang, Helen Hsieh, Son Pham
-
Publication number: 20140342401Abstract: The present invention relates to a transfected mammalian host cell whose ability to secrete a foreign protein has been enhanced by using a foreign gene expression vector having a promoter derived from a human gene, and a method for producing the foreign protein using the host cell. A method for enhancing the production of a foreign protein to be used in a pharmaceutical protein product in a host cell such as a cultured mammalian cell is provided. A promoter derived from a human gene having a promoter activity higher than that of a cytomegalovirus (CMV) promoter in a host cell such as a cultured mammalian cell is provided.Type: ApplicationFiled: May 28, 2014Publication date: November 20, 2014Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventor: Kenji Murakami
-
Publication number: 20140335053Abstract: The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.Type: ApplicationFiled: May 22, 2014Publication date: November 13, 2014Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Rong-Fu Wang, Steven A. Rosenberg, Gang Zeng
-
Publication number: 20140335565Abstract: The present invention provides a method capable of producing a natural or recombinant protein in high yield. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses cysteine sulfinic acid decarboxylase and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide. Hamster cysteine sulfinic acid decarboxylase, a DNA encoding the same, a recombinant vector and a transformed cell are also provided.Type: ApplicationFiled: August 1, 2014Publication date: November 13, 2014Inventors: Hisahiro Tabuchi, Satoshi Tainaka, Tomoya Sugiyama
-
Publication number: 20140336236Abstract: Novel ALK and NTRK1 fusion molecules and uses are disclosed.Type: ApplicationFiled: April 21, 2014Publication date: November 13, 2014Applicant: FOUNDATION MEDICINE, INC.Inventors: Maureen T. Cronin, Doron Lipson, Roman Yelensky
-
Publication number: 20140328875Abstract: Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.Type: ApplicationFiled: December 17, 2013Publication date: November 6, 2014Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer
-
Publication number: 20140329250Abstract: The invention provides calcium-binding photoproteins which can detect light emission with a higher sensitivity. The proteins of the invention comprising the amino acid sequence of SEQ ID NO: 2 can be used for the detection and measurement of calcium ions. The proteins of the invention are useful as reporter proteins, luminescent markers, etc. The polynucleotides of the invention are useful as reporter genes, etc.Type: ApplicationFiled: May 30, 2014Publication date: November 6, 2014Inventors: Satoshi INOUYE, Yuiko SAHARA
-
Publication number: 20140322758Abstract: The present invention provides, among other things methods of increasing cell density, viability and/or titer in a cell culture including steps of adding a composition comprising iron to the cell culture.Type: ApplicationFiled: October 9, 2012Publication date: October 30, 2014Inventors: Wenge Wang, Yen-Tung Luan, Denis Drapeau
-
Publication number: 20140315806Abstract: The present invention relates to veterinary decorin compositions and methods of their production.Type: ApplicationFiled: April 22, 2014Publication date: October 23, 2014Applicant: CATALENT PHARMA SOLUTIONS, LLCInventor: Gregory T. Bleck